Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco, US, has announced the enrollment of the first patient in the Phase Ia/B study for its investigational drug GTA182. The dosage escalation study aims to assess the safety, efficacy, and pharmacokinetics of the small molecule compound in patients with advanced solid tumors exhibiting MTAP deficiency, either as a monotherapy or in combination with the standard of care.
GTA182: A Selective PRMT5 Inhibitor Developed through AI-Guided Drug Discovery
GTA182 is a highly selective PRMT5 inhibitor that was in-house developed by Apeiron Therapeutics using its artificial intelligence (AI)-guided drug discovery platform. Pre-clinical studies have demonstrated GTA182’s over 100-fold selectivity towards MTAP deficient tumor cell lines, highlighting its potential as a targeted therapy for patients with this specific deficiency.
Implications for Cancer Treatment and Drug Development
The initiation of the Phase Ia/B study marks a significant step in the clinical development of GTA182 and underscores Apeiron Therapeutics’ commitment to leveraging advanced technologies in drug discovery and development. The study’s findings could potentially lead to new treatment options for patients with advanced solid tumors and MTAP deficiency, offering a more personalized approach to cancer therapy.-Fineline Info & Tech
Leave a Reply